Motpoly XR

How Does Motpoly XR Work?

Motpoly XR (lacosamide) works through a unique mechanism that distinguishes it from most other antiepileptic drugs. It selectively enhances the slow inactivation of voltage-gated sodium channels in neurons. Sodium channels control the electrical signals neurons use to communicate. When sodium channels become hyperactive, neurons fire abnormally — triggering seizures. By enhancing the "slow inactivation" state (the longer rest period a channel can enter after repeated firing), lacosamide stabilizes overactive neuronal membranes and reduces the abnormal sustained electrical activity that causes seizures.

This mechanism differs importantly from traditional sodium channel-blocking AEDs like carbamazepine, phenytoin, lamotrigine, and oxcarbazepine, which target the fast inactivation state. Because lacosamide targets a different part of the same channel cycle, it can provide complementary seizure control when added to these other drugs and has a distinct pharmacodynamic profile.

The extended-release bead technology in Motpoly XR delivers lacosamide gradually over 24 hours, maintaining stable plasma concentrations. Steady-state is achieved in approximately 4 days of once-daily dosing. The half-life is approximately 16 hours. This steady plasma level supports consistent seizure control and may reduce peak-dose side effects (such as dizziness and double vision) compared to the twice-daily immediate-release formulation.

How Hard Is It to Find Motpoly XR in Stock?

Motpoly XR is not listed on the FDA's drug shortage database as of 2026 — the supply chain is intact and the drug is being manufactured. However, finding it at your local pharmacy can require more effort than older, generic AEDs. As a newer brand-name medication (FDA-approved 2023) with limited prescriber adoption and no generic equivalent, many retail pharmacies do not routinely stock it. Stock varies considerably by location and chain.

The primary access barriers are: limited pharmacy stocking (because demand at individual locations is still building), insurance prior authorization requirements (most plans require PA before covering Motpoly XR), and its high retail cash price ($1,143–$1,565/month). Large chain pharmacies (CVS, Walgreens, Walmart Pharmacy) and mail-order pharmacies are most likely to stock or be able to quickly order it.

If your pharmacy doesn't have Motpoly XR, ask them to special order it — most can have it within 1–2 business days. Or use medfinder to have pharmacies near you checked on your behalf so you can quickly identify which ones have it in stock.

Who Can Prescribe Motpoly XR?

As a Schedule V controlled substance, Motpoly XR can be prescribed by any licensed healthcare provider with DEA registration authority. In practice, prescribers are most commonly:

Neurologists — the primary specialists for epilepsy; most likely to initiate Motpoly XR therapy

Epileptologists — neurologists with subspecialty training in epilepsy; found at comprehensive epilepsy centers

Pediatric neurologists — for pediatric patients weighing at least 50 kg

Primary care physicians (PCPs) — often manage refills for stable epilepsy patients established on therapy by a neurologist

Nurse practitioners (NPs) and physician assistants (PAs) — with prescriptive authority in most states, particularly those in neurology practices

Telehealth prescribing is available for Motpoly XR in most states. As a Schedule V controlled substance, it has fewer telehealth prescribing restrictions than higher-schedule medications. Telehealth is most appropriate for refills and follow-up care; an initial in-person neurological evaluation is generally recommended before starting any AED for a new seizure disorder.

Is Motpoly XR a Controlled Substance?

Yes. Motpoly XR is a federally controlled substance classified as Schedule V (CV) by the DEA. Schedule V is the least restrictive schedule, indicating some potential for abuse or dependence — lower than opioids (Schedule II–III) or benzodiazepines (Schedule IV), but still regulated. Lacosamide's abuse potential is related to its CNS effects (euphoria reported in clinical studies at high doses).

Practical implications of Schedule V status include: a prescription is required from a licensed prescriber with DEA registration; pharmacies must maintain controlled substance records for Motpoly XR; some smaller pharmacies may choose not to stock it; and patients should keep their supply in a secure location. Motpoly XR may be prescribed via telehealth in most states under current DEA regulations.

Never share Motpoly XR with anyone else. Sharing a controlled substance is illegal and the medication could harm someone who has not been evaluated by a physician. If you no longer need Motpoly XR, dispose of it properly through an authorized drug take-back location.

Common Side Effects of Motpoly XR

The most frequently reported side effects of Motpoly XR include:

Dizziness — most common, especially during dose initiation or increases

Double vision (diplopia) — often dose-related and temporary

Headache

Nausea — taking with food may help

Somnolence (sleepiness)

Ataxia — coordination problems, unsteadiness

Serious Side Effects — Contact Your Doctor Immediately

Suicidal thoughts or actions: AED class warning — approximately 1 in 500 patients; watch for mood changes, depression, agitation

Cardiac arrhythmias / PR interval prolongation: Irregular heartbeat, AV block, syncope; rare but potentially serious — call doctor immediately for chest discomfort or fainting

DRESS / Multi-organ hypersensitivity: Rash, fever, swollen glands, jaundice — discontinue immediately

Status epilepticus from abrupt discontinuation: Never stop Motpoly XR suddenly — always taper under medical supervision

Final Thoughts on Motpoly XR

Motpoly XR (lacosamide extended-release) represents an important advancement in epilepsy management — bringing the proven efficacy of lacosamide into a once-daily formulation that can improve adherence and reduce peak-dose side effects. For patients with partial-onset seizures or PGTC seizures who benefit from lacosamide therapy, the convenience of once-daily dosing is clinically meaningful. Its unique slow sodium channel inactivation mechanism provides a pharmacodynamic rationale for use alongside traditional AEDs.

The primary challenges with Motpoly XR are practical: its high list price ($1,143–$1,565/month without assistance), brand-only status with no generic equivalent, insurance prior authorization requirements, and limited stocking at many retail pharmacies. Fortunately, the Aucta Pharmaceuticals copay savings card brings costs to as low as $10/month for eligible commercially insured patients, and the patient assistance program serves those without insurance.

If you're having difficulty finding Motpoly XR in stock at your pharmacy, medfinder can help. medfinder calls pharmacies near you to check which ones have your specific medication in stock, then texts you the results — saving hours of frustrating calls and ensuring you can maintain uninterrupted access to your seizure medication.